To estimate the risk of being in institution with vision impairment. METHODS: Two national surveys were pooled together: 1) 2075 institutions (children or adults with handicap, old people and psychiatric centers) were selected at random from the French Health Ministry files in 18 predefined strata. Of the 15,403 subjects taken at random, 14,603 interviews (94.9%) documented handicap; and 2) Level of handicap was documented in a randomized, stratified sample of 356,208 citizens living in the community. From this sample, 21,760 subjects were further selected at random and 16,945 persons were interviewed. Handicaps (vision, audition, speaking, brain, visceral, motor and other) and activity of daily living (ADL) were then collected. The odds-ratio (OR) of being in institution was estimated using stepwise logistic regressions with age, geographical area, handicaps and ADL as co-variables. RESULTS: Patients in institution were more often female (64.3% versus 52.4%) and older (68.7 versus 38.0 years old) then patient living at home. They more often had handicaps (OR-speaking: 6.56; brain: 6.39; motor: 4.40; visceral: 2.87; audition: 2.37; other: 1.39). They were less often able to perform their ADL (46.2% versus 97.1%) without assistance. The OR to be in institution when having vision handicap was 8.40 without adjustment. This figure became 1.53 after adjustment on age, geographical area and other handicaps and 1.24 after adjustment on age, geographical area and ADL. CONCLUSION: Vision handicap is an independent risk factor of institutionalization. Preserving vision on long term might reduce or postpone old subject's institutionalization by controlling incapacity and dependency.
1
Quinze-Vingts Centre Hospitalier National d'Ophtalmologie, Paris, France; 2 Université de Bretagne-Sud, Vannes, France; 3 Alcon, Rueil-Malmaison, France OBJECTIVES: To issue orthogonal scores from the 52 standardized data collected by a Humphrey visual field (VF) perimetry that maximize between-variance and minimize within-variance. METHODS: 437 VF were collected and classified into 7 clinical groups: irregularities of VF (IVF), Nasal step (NaS), Arcuate scotoma (AC), Para-central scotoma (PCS), Blind spot enlargement (BSE), Diffuse deficit (DD), Advanced deficit (AD). Number and contents of scores were identified using a principal component analysis (Varimax) followed by an ascending hierarchical clustering analysis. Internal consistency was checked with Cronbach alpha. Scores were compared across the clinical groups with an Anova. RESULTS: Patients totaling 54.7% of the patients were older than 60. Mean defect was -9.21 on average and PSD was 6.50. Six scores were identified: 4 peripheral scores (Nasal Superior NS, Nasal Inferior NI, Temporal Superior TS, Temporal Inferior TI) and 2 para-central scores (superior PCSS, inferior PCSI). Cronbach alphas were always between 0.90 and 0.97. The six scores decreased simultaneously from IVF, DD to AD. AC had lower scores in NS, NI and TS. PCS had a lower PCSS. BSE had lower scores in TS and TI. NaS had lower scores in NS and NI. CONCLUSION: Six orthogonal scores were found to be optimal from the Humphrey perimetry matrix. Internal reliability was good. Ability to discriminate between clinical subgroups was found. Further analyses on longitudinal data need to be performed to confirm our findings.
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COST AND EFFECTIVENESS OF BRINZOLAMIDE VERSUS DORZOLAMIDE IN THE TREATMENT OF GLAUCOMA: AN ANALYSIS CONDUCTED USING THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE
Lafuma A 1 ,Voinet C 1 , Berdeaux G 2 1 Cemka, Bourg-La-Reine, France; 2 Alcon, Rueil-Malmaison, France OBJECTIVE: To compare the cost and effectiveness of brinzolamide and dorzolamide using data collected in the United-Kingdom General Practitioner Research Database METHODS: Files of patients with a diagnosis of ocular hypertension or glaucoma, or treated with a topical IOP lowering treatment were extracted. Patients starting treatment with dorzolamide or brinzolamide from August 2000 were selected. A treatment failure was defined as a regimen change (adding or removing a topical treatment). Time to treatment failure was compared using a Cox model. The economic perspective was that of the NHS. The annual cost of therapy changes by treatment line (first, second, etc.) was calculated for year 2000; visit, medication and hospitalization costs were included. RESULTS: Of 49,799 patients selected, 146 were treated with brinzolamide and 1230 with dorzolamide. No statistically significant differences were found between the 2 groups in terms of patient and disease characteristics. Patients averaged 72.9 years old and were 56% female. Prescriptions totaling 21.1% of the prescriptions involved monotherapy and 14.8% were for first line treatment.
After 1 year, 29.8% of the brinzolamide patients experienced a treatment failure compared to 46.0% with dorzolamide (P < 0.01). Seventy-five percent of the patients had a treatment duration longer than 203 days when treated with brinzolamide versus 140 days with dorzolamide. The probability of a failure was 1.61 (P < 0.02) times higher with dorzolamide, after adjusting for treatment line and the number of drugs prescribed. The yearly glaucoma treatment cost for a patient with a treatment failure was found to be higher (GBP 15.21) than for patients who continued their treatment. CONCLUSION: In comparison to dorzolamide, patients treated with brinzolamide experienced fewer treatment failures, leading to cost savings.
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COMPARISON OF THE CLINICAL EFFICACY AND COST-EFFECTIVENESS OF LUMIGAN AND XALATAN IN THE TREATMENT OF GLAUCOMA
Roberts G 1 , Buchholz P 2 , Holmstrom S 3 , Finck K 3 , Gillard S 4 , Warner J 4 , Teale C 1 1 Allergan Ltd, Buckinghamshire, United Kingdom; 2 Allergan, Ettlingen, Germany; 3 Allergan, Mougins, France; 4 ABACUS International, Oxfordshire, United Kingdom
OBJECTIVES:
The purpose of this study was to compare the intraocular pressure (IOP)-lowering efficacy and cost-effectiveness of Lumigan (Bimatoprost) versus Xalatan (Latanoprost) in glaucoma patients. METHODS: A Markov model was developed to compare the cost-effectiveness of Lumigan initiated treatment with Xalatan initiated treatment in the context of the French Health care system. The model uses a timeframe of one year and data from published randomised clinical trials, which included a total of 249 patients. Patients were allowed to switch medication up to a maximum of two times if target IOP was not met or adverse events occurred and each switch was associated with a physician visit (cost: €23.00 each). Drug costs used were €20.10 for Lumigan and €17.67 for Xalatan. A probabilistic analysis was performed using 1000 Monte Carlo simulations. The primary outcome measures were the number of months patients spent at IOP < 17 mmHg and the cost per month at IOP < 17 mmHg. Sensitivity analyses were conducted varying the target IOPs. RESULTS: More patient months at IOP < 17 mmHg were achieved by patients on Lumigan versus Xalatan initiated therapy (9.7 versus 9.3; P < 0.05). Lumigan initiated therapy was also associated with fewer annual physician visits per patient (5.14 compared to 5.48; P < 0.001). The cost per patient per month at IOP < 17 mmHg was €41.96 for patients on Lumigan compared to €44.60 for those on a Xalatan initiated therapy. The results of the sensitivity analysis determined that at target IOPs of 14 to 17 mmHg there was a lower average annual treatment cost per patient for Lumigan initiated patients. CONCLUSIONS: Lumigan initiated treatment is more cost-effective than Xalatan initiated treatment at target IOPs between 14-17 mmHg. 
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ECONOMIC EVALUATION OF LATANOPROST AS FIRST LINE GLAUCOMA THERAPY IN 6 EUROPEAN COUNTRIES
OBJECTIVE:
The aim of glaucoma treatment is to delay progression of the disease to blindness, by lowering intra-ocular pressure (IOP). Clinical trials have shown that latanoprost (Xalatan®, Pfizer) achieves better IOP control than beta-blockers. We assessed the costeffectiveness of latanoprost as 1st-line therapy, compared to beta-blockers, in Austria, Belgium, France, Germany, Italy and the UK. METHODS: Clinical outcomes and resource utilisation data were obtained from a retrospective chart review study of glaucoma patients initially treated with latanoprost or beta-blocker in Germany, Italy, Spain, and the UK. A Markov model was used to calculate the number of months of IOP control and total costs (including drugs, physician visits, diagnostic tests and surgeries) per patient over 2 years from a third-party payer perspective. The model was estimated by Monte Carlo simulation. The incremental cost per IOPcontrolled month was reported for each country and variability around this ratio was examined. RESULTS: Seventy-three percent of patients remained on treatment with latanoprost, compared to 29% with beta-blocker, over 2 years. The higher acquisition cost of latanoprost was partly offset by lower surgery costs. The ICER ranged from €24.94 (95% CI: 20.68-30.11) per IOP-controlled month, for France, to €272.84 (251.24-297.17), for Germany. Sensitivity analyses showed that survival on therapy, the duration of medication bottles and parameters related to surgery costs were the main drivers of cost-effectiveness. CONCLUSIONS: Differences between countries were mainly attributable to variation in drug and surgery unit costs. First-line treatment with latanoprost is predicted to be cost-effective if decisionmakers value the control of IOP at a minimum of approximately €25 per month in France, €45 per month in Belgium, UK and €275 per month in Germany, under the current system and costs of care. Relatively low unit costs for surgery and the drug co-payment system contributed to the higher ICER in Germany.
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TREATMENT DURATION AS A COST DRIVER OF GLAUCOMA CARE: A LIFE-LONG SOCIETAL PERSPECTIVE IN FRANCE, GERMANY AND THE NETHERLAND
Lafuma A 1 ,Voinet C 1 , Berdeaux G 2 1 Cemka, Bourg-La-Reine, France; 2 Alcon, Rueil-Malmaison, France
